The synthesis of recombinant human transforming growth factor beta-1 proprotein (TGFB1) involves isolating the target gene that codes for the human TGFB1 (281-390aa), which is fused with an N-terminal 6xHis-tag gene. This fused gene is cloned into an appropriate expression vector and introduced into E.coli cells via transformation. The positive E.coli cells are induced to express the recombinant TGFB1 protein, which is harvested from the cell lysate. The collected proteins undergo affinity chromatography purification. Its purity reaches over 90%.
TGFB1 is a crucial cytokine involved in various biological processes such as growth, repair, inflammation, fibrosis, cell proliferation, and differentiation [1-5]. TGFB1 induces the secretion of platelet-derived growth factors, which further contribute to cellular responses such as mitogenesis [6][7]. It regulates extracellular matrix rigidity and the differentiation of cells like cardiac fibroblasts into myofibroblasts [8]. Studies have demonstrated the involvement of TGFB1 in diseases like fibrotic liver diseases and pulmonary fibrosis [9][10].
Furthermore, TGFB1 has been associated with the modulation of gene expression and cell behavior in response to various stimuli, including other growth factors [11][12]. It interacts with different signaling pathways, influencing processes like cell migration, transformation, and colony growth [13]. The presence of TGFB1 in active liver diseases and its impact on fibrosis progression underscores its importance in disease development and progression [9].
References:
[1] A. Piattelli, C. Rubini, M. Fioroni, L. Favero, & R. Strocchi, Expression of transforming growth factor‐beta 1 (tgf‐beta 1) in odontogenic cysts, International Endodontic Journal, vol. 37, no. 1, p. 7-11, 2004. https://doi.org/10.1111/j.1365-2591.2004.00739.x
[2] J. Nüchel, S. Ghatak, A. Zuk, A. Illerhaus, M. Mörgelin, K. Schönbornet al., Tgfb1 is secreted through an unconventional pathway dependent on the autophagic machinery and cytoskeletal regulators, Autophagy, vol. 14, no. 3, p. 465-486, 2018. https://doi.org/10.1080/15548627.2017.1422850
[3] Y. Kong, F. Sun, X. Wang, & L. Shi, Naringin attenuates the fibrosis of transforming growth factor-beta 1 induced human embryonic lung fibroblasts through nuclear factor kappa b pathway, IJPS, vol. 85, no. 2, 2022. https://doi.org/10.36468/pharmaceutical-sciences.1107
[4] R. Watts and J. Ware, Isolation and characterization of transforming growth factor beta response variants from human prostatic tumor cell lines, The Prostate, vol. 21, no. 3, p. 223-237, 1992. https://doi.org/10.1002/pros.2990210306
[5] E. Helseth, G. Unsgaard, A. Dalen, & R. Vik, Effects of type beta transforming growth factor in combination with retinoic acid or tumor necrosis factor on proliferation of a human glioblastoma cell line and clonogenic cells from freshly resected human brain tumors, Cancer Immunology Immunotherapy, vol. 26, no. 3, 1988. https://doi.org/10.1007/bf00199941
[6] K. Win, F. Charlotte, A. Mallat, D. Cherqui, N. Martin, P. Mavieret al., Mitogenic effect of transforming growth factor-β1 on human ito cells in culture: evidence for mediation by endogenous platelet-derived growth factor, Hepatology, vol. 18, no. 1, p. 137-145, 1993. https://doi.org/10.1002/hep.1840180121
[7] V. Tsang and P. Tran, Pulmonary vein stenosis: challenges ahead, Journal of Thoracic and Cardiovascular Surgery, vol. 150, no. 4, p. 776, 2015. https://doi.org/10.1016/j.jtcvs.2015.07.024
[8] N. Cho, S. Razipour, & M. McCain, Featured article: tgf-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts, Experimental Biology and Medicine, vol. 243, no. 7, p. 601-612, 2018. https://doi.org/10.1177/1535370218761628
[9] P. Nagy, Z. Schaff, & K. Lapis, Immunohistochemical detection of transforming growth factor-β1 in fibrotic liver diseases, Hepatology, vol. 14, no. 2, p. 269-273, 1991. https://doi.org/10.1002/hep.1840140211
[10] K. Böhm, N. Teich, A. Hoffmeister, J. Mössner, V. Keim, H. Bödekeret al., Transforming growth factor-beta-1 variants are not associated with chronic nonalcoholic pancreatitis, Pancreatology, vol. 5, no. 1, p. 75-80, 2005. https://doi.org/10.1159/000084829
[11] M. Story, K. Hopp, D. Meier, F. Begun, & R. Lawson, Influence of transforming growth factor β1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate‐derived fibroblasts, The Prostate, vol. 22, no. 3, p. 183-197, 1993. https://doi.org/10.1002/pros.2990220302
[12] J. Geller, L. Sionit, A. Baird, M. Kohls, K. Connors, & R. Hoffman, In vivo and in vitro effects of androgen on fibroblast growth factor‐2 concentrations in the human prostate, The Prostate, vol. 25, no. 4, p. 206-209, 1994. https://doi.org/10.1002/pros.2990250406
[13] J. Banyard, C. Barrows, & B. Zetter, Differential regulation of human thymosin beta 15 isoforms by transforming growth factor beta 1, Genes Chromosomes and Cancer, vol. 48, no. 6, p. 502-509, 2009. https://doi.org/10.1002/gcc.20659
